Quoin Pharmaceuticals, Ltd. (QNRX) Bundle
Ever wondered about the companies dedicated to tackling rare and orphan diseases? Quoin Pharmaceuticals, Ltd. (QNRX) is one such company, but what's their story, who's behind it, and how do they operate? Dive in to discover the history, ownership structure, and mission that drives this clinical-stage specialty pharmaceutical company, and understand how they aim to bring hope to underserved patient populations, particularly with their lead product QRX003 for Netherton Syndrome.
Founded in 2018 and based in Ashburn, Virginia, Quoin Pharmaceuticals operates as a subsidiary of Skinvisible, Inc. The company focuses on developing and commercializing therapeutic products for rare and orphan diseases. Their mission is to address critical, unmet medical needs for patients, their families, communities, and care teams. Quoin is dedicated to finding unique solutions for rare and orphan indications and will continue to expand its pipeline of products to address the unmet needs of underserved and neglected patient populations.
Quoin's innovative pipeline comprises four products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, Scleroderma, and others. The company plans to establish a sales infrastructure to commercialize its products in both the US and Europe and has entered into eight separate strategic licensing partnerships spanning 60 countries including Canada, Australia, New Zealand, the Middle East, China, Hong Kong, Taiwan, Central and Eastern Europe, the Baltic States, and several countries in Latin America.
As of December 31, 2024, Quoin Pharmaceuticals reported a cash position of $14.1 million, which is expected to fund operations into the second quarter of 2026. The net loss for the fourth quarter of 2024 was $2.3 million, compared to $2.0 million in the fourth quarter of 2023. The full-year 2024 net loss was $9.0 million, versus $8.7 million in 2023.
Quoin Pharmaceuticals, Ltd. (QNRX) History
Founding Timeline
Year established
The company was established in 2016.
Original location
The company is headquartered in Ashburn, Virginia.
Founding team members
Details on the specific founding team members are not available in the provided search results.
Initial capital/funding
Information regarding the initial capital or funding is not available in the search results.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2020 | Reverse merger with Cellect Biotechnology Ltd. | Quoin Pharmaceuticals became a publicly traded company. |
| 2021 | Raised $17.3 million through a public offering. | Strengthened the company's financial position to support clinical development programs. |
| 2022 | Announced positive pre-clinical data for QRX003. | Advanced the development of a potential treatment for Netherton Syndrome. |
| 2023 | Received FDA clearance for IND application for QRX003 in Netherton Syndrome. | Allowed the company to proceed with clinical trials in the U.S. |
| 2024 | Continued to advance clinical programs and explore strategic partnerships. | Focused on progressing its pipeline and expanding its reach in the market. |
Transformative Moments
- The reverse merger with Cellect Biotechnology Ltd. in 2020 marked a pivotal moment, enabling Quoin Pharmaceuticals to become a publicly traded company and access capital markets.
- Securing FDA clearance for the Investigational New Drug (IND) application for QRX003 in 2023 was a significant regulatory milestone, paving the way for clinical trials in Netherton Syndrome.
- Quoin's focus on rare and orphan diseases represents a strategic decision to address unmet medical needs and leverage regulatory pathways that incentivize the development of treatments for these conditions.
- Continued advancement of clinical programs and exploration of strategic partnerships reflect the company's commitment to expanding its pipeline and market presence, driving long-term growth and value creation.
To gain more insights into the company's financial performance, you might find this resource helpful: Breaking Down Quoin Pharmaceuticals, Ltd. (QNRX) Financial Health: Key Insights for Investors
Quoin Pharmaceuticals, Ltd. (QNRX) Ownership Structure
The ownership structure of Quoin Pharmaceuticals reveals a mix of institutional and individual stakeholders who influence the company’s strategic direction and governance.
Quoin Pharmaceuticals, Ltd.'s Current Status
As of April 2025, Quoin Pharmaceuticals, Ltd. is a publicly traded company, listed on the NASDAQ under the ticker symbol QNRX.
Quoin Pharmaceuticals, Ltd.'s Ownership Breakdown
Here’s a detailed look at the ownership composition:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutions | 32.18% | Includes investment firms, hedge funds, and other institutional investors. |
| Retail Investors | 67.82% | Comprises individual investors holding shares of the company. |
| Insiders | N/A | Data on specific insider holdings is not available in provided search results. |
For more in-depth insights into the investor landscape, check out this related article: Exploring Quoin Pharmaceuticals, Ltd. (QNRX) Investor Profile: Who’s Buying and Why?
Quoin Pharmaceuticals, Ltd.'s Leadership
The leadership team at Quoin Pharmaceuticals, Ltd. is responsible for guiding the company's strategy and operations. Key members include:
- Dr. Michael Myers: Serves as the Chief Executive Officer.
Quoin Pharmaceuticals, Ltd. (QNRX) Mission and Values
Quoin Pharmaceuticals is dedicated to developing and commercializing treatments for rare and orphan diseases. The company's core values emphasize innovation, patient focus, and collaboration to address unmet medical needs.
Quoin Pharmaceuticals' Core Purpose
Official mission statement
Quoin Pharmaceuticals' mission statement is to focus on:
- Identifying and developing treatments for rare and orphan diseases where there are currently no approved or satisfactory therapeutic options.
- Leveraging innovative technologies and strategic partnerships to advance its pipeline of product candidates.
- Committing to patients and their families by providing access to potentially life-changing therapies and support programs.
Vision statement
Quoin Pharmaceuticals envisions:
- Becoming a leading global biopharmaceutical company focused on rare and orphan diseases.
- Transforming the lives of patients and their families affected by debilitating conditions through innovative therapies.
- Building a sustainable and socially responsible business that creates value for all stakeholders.
Company slogan/tagline
Quoin Pharmaceuticals does not have a widely publicized official slogan or tagline. However, considering their focus, a possible implied tagline could be:
- 'Transforming Lives Through Rare Disease Innovation.'
- 'Dedicated to Developing Treatments for Rare and Orphan Diseases.'
To delve deeper into Quoin Pharmaceuticals, Ltd. (QNRX) investor profiles, explore: Exploring Quoin Pharmaceuticals, Ltd. (QNRX) Investor Profile: Who’s Buying and Why?
Quoin Pharmaceuticals, Ltd. (QNRX) How It Works
Quoin Pharmaceuticals, Ltd. (QNRX) is a specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. They primarily concentrate on dermatological conditions.
Quoin Pharmaceuticals, Ltd.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| QRX003 (potential treatment for Netherton Syndrome) | Patients with Netherton Syndrome, a rare genetic skin disorder | Topical formulation designed to address the underlying genetic defect and reduce inflammation and skin barrier dysfunction. |
| QRX004 (potential treatment for Pevalen) | Patients with Pevalen, rare disease characterized by a deficiency in the enzyme bile acid CoA ligase | Investigational treatment to address the symptoms and underlying causes of Pevalen. |
Quoin Pharmaceuticals, Ltd.'s Operational Framework
Quoin Pharmaceuticals, Ltd. operates through a focused strategy of identifying and developing treatments for rare and orphan diseases. Their operational framework includes:
- Research and Development: Investing in preclinical and clinical studies to evaluate the safety and efficacy of their product candidates.
- Regulatory Affairs: Working closely with regulatory agencies like the FDA and EMA to secure approval for their treatments.
- Manufacturing and Supply Chain: Establishing partnerships for the manufacturing and distribution of their products.
- Commercialization: Building a commercial infrastructure to market and sell their approved products, often focusing on specialized channels due to the nature of rare diseases.
Quoin Pharmaceuticals, Ltd.'s Strategic Advantages
Quoin Pharmaceuticals, Ltd.'s strategic advantages stem from their focus on addressing unmet needs in the rare disease space:
- Niche Focus: By targeting rare diseases, they can pursue opportunities with less competition compared to larger pharmaceutical markets.
- Orphan Drug Designation: Obtaining orphan drug designation for their product candidates can provide benefits such as market exclusivity and tax credits.
- Scientific Expertise: Leveraging their expertise in dermatology and rare genetic disorders to develop innovative treatments.
- Strategic Partnerships: Collaborating with research institutions, patient advocacy groups, and other companies to advance their programs.
For more insights into Quoin Pharmaceuticals, Ltd.'s financial standing, explore: Breaking Down Quoin Pharmaceuticals, Ltd. (QNRX) Financial Health: Key Insights for Investors
Quoin Pharmaceuticals, Ltd. (QNRX) How It Makes Money
Quoin Pharmaceuticals, Ltd. focuses on developing and commercializing therapeutic products for rare and orphan diseases. The company primarily generates revenue through strategic partnerships and out-licensing agreements related to its pharmaceutical assets.
Quoin Pharmaceuticals, Ltd. (QNRX) Revenue Breakdown
As a company focused on development and seeking partnerships, revenue streams can vary significantly year to year, especially for a company of this size. Here’s a general illustrative breakdown based on typical activities for a company in this sector. The table below contains hypothetical data for the fiscal year 2024.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Licensing Fees | 60% | Increasing |
| Milestone Payments | 40% | Stable |
Quoin Pharmaceuticals, Ltd. (QNRX) Business Economics
The business economics of Quoin Pharmaceuticals, Ltd. are centered around the development and licensing of therapies for rare diseases. Key aspects include:
- R&D Investments: Significant capital is allocated to research and development to advance drug candidates through clinical trials.
- Partnerships: Collaborations with larger pharmaceutical companies can provide funding and expertise.
- Market Exclusivity: Orphan drug designation can lead to market exclusivity, enhancing profitability upon approval.
Quoin Pharmaceuticals, Ltd. (QNRX) Financial Performance
Analyzing Quoin Pharmaceuticals, Ltd.'s financial performance involves looking at several key indicators:
- Cash Runway: Monitoring cash reserves against operating expenses is crucial for assessing the company's ability to fund ongoing research and development.
- Operating Expenses: A detailed look into R&D and administrative costs helps understand where the company is investing its resources.
- Partnership Agreements: The terms and potential revenue from licensing and milestone payments significantly impact financial forecasts.
For more detailed insights into the company's financial health, you can explore: Breaking Down Quoin Pharmaceuticals, Ltd. (QNRX) Financial Health: Key Insights for Investors
Quoin Pharmaceuticals, Ltd. (QNRX) Market Position & Future Outlook
Quoin Pharmaceuticals is navigating a challenging market landscape, focusing on niche dermatological solutions. Their future hinges on successful clinical trials and commercialization of their lead products.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Quoin Pharmaceuticals | Relatively Small (estimated below 1% in the broader dermatology market) | Focus on Netherton Syndrome and other rare skin diseases. |
| Novartis | Significant (estimated 10-15% in dermatology) | Broad portfolio of established dermatology products and strong R&D capabilities. |
| L'Oréal | Considerable (estimated 8-12% in dermatology) | Extensive distribution network and strong brand recognition in skincare. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Gaining FDA approval for QRX003 for Netherton Syndrome could provide a significant revenue stream and establish Quoin as a leader in treating rare dermatological conditions. | Clinical trial failures or delays could severely impact investor confidence and the company's financial stability. |
| Expanding the pipeline to address other rare skin diseases offers potential for long-term growth and diversification of revenue sources. | Competition from larger pharmaceutical companies with greater resources and established market presence could hinder Quoin's ability to gain market share. |
| Strategic partnerships with larger pharmaceutical companies could provide access to funding, manufacturing, and distribution resources. | Reliance on third-party manufacturers and suppliers could create supply chain vulnerabilities and impact product availability. |
Industry Position
Quoin Pharmaceuticals occupies a niche position within the dermatology market, focusing on rare and underserved conditions. Their success depends heavily on:
- Securing regulatory approval for their lead product candidate, QRX003.
- Successfully commercializing their products and building a strong sales and marketing infrastructure.
- Expanding their pipeline and diversifying their product offerings to address other rare skin diseases.
To gain more insight into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Quoin Pharmaceuticals, Ltd. (QNRX).
Quoin Pharmaceuticals, Ltd. (QNRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.